2ο Οδοντιατρικό Forum: Πρόληψη, ενημέρωση και πολιτικές υγείας απέναντι στην υπερκατανάλωση ζάχαρης

This advanced course on CRS, HIPEC and intraperitoneal treatments for peritoneal malignancies aims at discussing evidence-based clinical decision-making in the management of primary and secondary peritoneal cancers. It will offer a multidisciplinary programme combining both practical aspects and theoretical problems. This year’s programme will feature debates and ‘pro-con’ sessions on key controversies in peritoneal surface oncology. In the wet-lab, the participants will have an opportunity to learn open and minimally invasive cytoreductive surgery (NEW).

AbstractThe gold standard of quality assessment of drugs is nowadays an HPLC using a reversed-phase (RP) column chromatography and aqueous buffers, acetonitrile, and/or methanol as mobile phase, combined with a UV detector. As many excipients and active pharmaceutical ingredients (APIs) do not have a chromophore, these compounds are not suitable for identification and quantification by UV detection. In this situation, the near-universal Charged Aerosol Detector (CAD) is an excellent alternative capable of detecting almost all non-volatile compounds. One critical thing to know is that the mobile phase composition—often dictated by solid phase chemistry—can influence the CAD response. In addition to RP techniques, chromatographers often apply ion pair chromatography (IPC), mixed mode (MMC), and hydrophilic interaction (HILIC) methods. We will discuss how these solid phases influence selectivity and sensitivity of the CAD when analyzing the purity of APIs such as amino acids, vigabatrin, ibandronate, atropine, and gabapentin, as well as excipients, e.g., fatty acids, PEGs, and polysorbates. These examples will demonstrate the versatility of HPLC-CAD for quantifying low concentrations of impurities in APIs and excipients. Sensitivity is of great importance in the quality control of drugs.Key Learning Objectives: Quality assurance by HPLC-CAD, enhancement of sensitivity, impurity profiling of APIs and excipients. Key learning and takeaways include:Explore on the critical yet increasingly complex challenge of impurity profiling of APIs and excipients in pharmaceutical analysisReview on enhancement of sensitivity in detection to uncover low-level impuritiesDiscover examples for quality assurance by HPLC-CAD analysis